Introduction
Hodgkin's disease (HD) is a lymphoma of relatively good prognosis. Currently, most patients are curable with standard therapy. However, *40% of patients are either refractory to initial treatment or relapse after achieving complete remission (Brice et al., 1996; Kennedy et al., 1998; Lohri et al., 1991) . Among them, 50% will not bene®t from any salvage therapy and will die from disease progression (Bartlett and Arackal, 2000) . In contrast to the non-Hodgkin lymphoma (NHL) International Prognostic Index, there is no consensual prognostic model for HD. The recent International Prognostic Score (IPS) has been developed for patients with advanced stage HD, but has limited predictive capability for early stage patients (Hasenclever and Diehl, 1998) . Today, no factor can reliably identify the patients whose disease will take a fatal course (Bartlett and Arackal, 2000) . Because of the increasing number of therapeutic options, there is a crucial need to identify new parameters that can accurately predict the natural history of disease and the eectiveness of treatment for each patient.
Hodgkin's disease is histologically heterogeneous and still poorly understood at the molecular level (see Staudt, 2000 for review) . So-called`classical' HD includes histological types II (nodular sclerosis) and III (mixed cellularity) (Harris et al., 1994; Staudt, 2000) . It is characterized by the presence of a low number of tumour cells (usually 55%), designated as Hodgkin/Reed-Sternberg (H/RS) cells, which reside in an abundant mixture of non-malignant reactive cells, including lymphocytes, histiocytes and eosinophils (Chan, 2001; Harris et al., 1994) . Recent molecular studies have suggested that, in most cases, H/RS originate from B cells at the germinal or post-germinal centre stage of dierentiation (Cossman et al., 1999; Theil et al., 2001) . The amount of reactive cells in HD is thought to be related to the level of activation of cytokines acting as paracrine or autocrine factors on cell survival and proliferation; numerous cytokines including IL1, IL5, IL6, IL7, IL8, IL10, TNF-a, LT-a, TGF-b, GM-CSF are indeed expressed in HD tissues Poppema and Van Den Berg, 2000) . The clinical course (such as B symptoms and immunosuppression) and the severity of the disease result from the complex molecular networks operating in tissues. For example, IL10 can modulate the immune response at several levels (Wakkach et al., 2000) . A comprehensive characterization of the biological alterations that take place in HD tissues could help understand the complexity of the disease and evaluate their prognostic and predictive relevance.
cDNA array technology allows simultaneous and quantitative measurement of the expression of many genes at the RNA level The Chipping Forecast, 1999) . Recently, it has been used to analyse many types of cancer (Bertucci et al., 2000; Bittner et al., 2000; Khan et al., 2001; Perou et al., 2000) , including acute leukaemias (Golub et al., 1999; Virtaneva et al., 2001 ) and lymphomas Dales et al., 2001; Li et al., 2001; Wellmann et al., 2000) . Correlations with clinical outcome has led to the identi®cation of molecular subgroups of nonHodgkin's lymphomas with distinct prognostic signi®-cance . We report here the analysis of the expression pro®les of *1000 arrayed selected cDNAs in a panel of normal and malignant lymphoid samples including Hodgkin's disease tissues.
Results

Gene expression profiling of lymphoid samples
We determined the expression pro®les of *1000 selected genes in 34 normal and malignant lymphoid samples, including 21 cases of HD (Table 1) . Puri®ed cells and cell lines were studied for comparison. The response to therapy and status of disease at the last follow-up visit allowed us to classify the patients with HD into two groups: GOHD for good outcome HD (complete response CR and alive without disease) and BOHD for bad outcome HD (progressive disease PD and death). Hierarchical clustering using the Gene Cluster program (Eisen et al., 1998 ) was ®rst applied to group genes on the basis of similarity of their expression patterns across all samples. It was then separately applied to NHL and benign samples, HD samples, and cell lines, to group samples on the basis of the similarity of their expression patterns. Results are displayed using the TreeView program in a colourcoded matrix (Figure 1 ): each column corresponds to a tissue sample and each row to a gene. A colour scale is used, in which red and green mean expression level higher and lower than the median, respectively; the magnitude of the deviation from the median is represented by the colour intensity. There was a great heterogeneity of gene expression pro®les between all samples with highly variable expression levels for many genes. Clustering resulted in the segregation of groups of correlated samples and of correlated genes. This is depicted in Figure 1 by prominent contiguous patches of red or green colour and by the branching pattern of dendrograms above the samples and next to the genes, whose length of branches re¯ects the relatedness between the samples of genes.
Clustering of NHL and benign samples (left panel) grouped benign samples in the same branch; in particular, puri®ed lymphocytes (LNT, LNB, T act., T rest.) were classi®ed together. The three HD cell lines displayed some degree of transcriptional heterogeneity, but clustered together and were separated from the ®broblastic cell line (right panel). As re¯ected by the dendrogram, gene expression pro®les of HD samples (central panel) were heterogeneous with a pro®le unique for each case. Clustering evidenced two main Figure 1 ). Inspection of the gene expression map showed some sets of genes whose expression signature was associated with the clinical outcome of patients (coloured bars in Figure 1 ). One gene cluster (brown bar) was markedly expressed in the branch I of GOHD cases and the HD cell lines. A second cluster (blue bar) was overexpressed in BOHD cases; this cluster included many genes overexpressed in the HFF ®broblastic cell line (it was thus designated the`®broblast signature') and underexpressed in NHL and benign samples in which the ®brotic component is expected to be low. A third gene cluster (orange bar) was downregulated in the BOHD cases and overexpressed in most HD cells lines.
Molecular classification of HD cases
Several studies examining thousands of arrayed genes have shown the potential of cDNA arrays to identify subsets of genes with expression pro®les correlated with survival of patients Bertucci et al., 2000; Bittner et al., 2000; Perou et al., 2000) . Thus to further explore the potential clinical interest of these three prominent gene clusters, we reclustered HD cases using only the expression levels of genes included in these clusters, excluding from the analysis the other groups of genes that may in¯uence the classi®cation ( Figure 2 ). The 21 HD samples segregated in three groups, named A, B and C. The con®dence for these groups revealed by hierarchical clustering was assessed by conducting the same analysis with another classi®cation algorithm k-means. Assigning three gene clusters and three sample clusters, we obtained exactly the same classi®cation (data not shown) suggesting the robustness of our clustering patterns. These groups were correlated with both histological type, response to therapy and survival. Group A (n=8) included all ®ve mixed cellularity cases, which clustered together in the same sub-branch, whereas groups B (n=7) and C (n=6) contained only nodular sclerosis cases. All patients from groups A and C experienced a CR after treatment, whereas group B included all ®ve patients with progressive disease; this dierence was statistically signi®cant (P50.001, w 2 test). Response to therapy correlated with survival, suggesting a prognostic interest of such a molecular classi®cation. The 5-year survival was signi®cantly better in groups A+C (92%) than in group B (29%) (P50.001, log-rank test). These dierences regarding response rate and survival remained signi®cant when we compared only the nodular sclerosis cases from groups B and C (P50.05, Fisher's test and P50.05, log-rank test, respectively). The prognostic classi®cation provided by our gene expression pro®ling had a better prediction than conventional staging in ®ve patients (Table 1) . Among these ®ve cases, four patients (samples 3883, 5234, 9201 and 10088) had been attributed an unfavourable prognosis using classical factors, but clustered with most GOHD cases in groups A and C, and, in agreement with this ®nding, experienced a favourable outcome. Conversely, one patient with fatal outcome (sample 18022), who had been attributed a favourable prognostic using classical factors, was molecularly classi®ed in group B with other BOHD cases.
Genes potentially relevant to molecular classification of HD
The identity of the genes included in the three discriminant clusters is detailed in Figure 2 . The ®rst cluster (blue bar,`®broblast signature') was upregulated in nodular sclerosis BOHD samples overall as compared to GOHD. It contained genes involved in angiogenesis, ®broblast activation and extracellular matrix modelling, such as endostatin (COL18A1), collagen VI (COL6A1), micro®brillar-associated protein 2 (MFAP2), matrix proteases (MMP2, MMP3) and their inhibitor TIMP1. Also detected was the overexpression of tumour necrosis factor a (TNF), the MK167 proliferation marker, cell adhesion molecules (CDH5, SELP, FAT), and growth factor receptors (PDGFRB, ERBB2). The second cluster (brown bar), overexpressed in the HD cell lines, was upregulated in nodular sclerosis GOHD (group C) overall as compared to nodular sclerosis BOHD (group B). It included many genes involved in positive apoptotic regulation such as APAF, BID, BAX, caspases (CASP6, CASP8), NOS3, TP53, TRAIL (TNFSF10), TRAILR1 (TNFSF10RA), TRAILR2 (TNFSF10RB), and in cell signalling, including cytokines and their receptors (IFNAR1, IL10, IL18, IL5RA, IL9R, IL13RA2), transduction molecules (STAT3, MAP2K6). Interestingly, some of them displayed highly correlated expression such as CASP6, IL10 and IL9R, or CASP8 and BID (red arrows in Figure 2 ). Other genes were involved in cell adhesion such as E-cadherin or integrins (ITGAL, ITGB4), and in the cell cycle (CDK2, CCNC, CDKN2A). The third cluster (orange cluster), overexpressed in most HD cell lines, was downregulated in all BOHD; it included genes with various functions such as the tumour suppressor genes PTEN and DCC, the mismatch repair gene PMS2, and two NOTCH genes. Figure 2 Gene expression-based classi®cation of HD samples and correlations with clinicopathological data. The 21 HD samples were reclustered using expression levels of the three subsets of genes identi®ed by coloured bars in Figure 1 . Three large groups of tumours were separated (A, B and C). Group A included all mixed cellularity HD samples (purple branches), group B included all nodular sclerosis samples associated with bad outcome (red numbers), and group C included only nodular sclerosis samples from patients with very favourable outcome. Genes are referenced using their HUGO abbreviation as used iǹ Locus Link' (http://www.ncbi.nlm.nih.gov/LocusLink/). The blue and orange gene clusters (left) were respectively upregulated and downregulated in BOHD samples overall as compared to GOHD samples. The brown gene cluster was upregulated in nodular sclerosis GOHD samples as compared to nodular sclerosis BOHD samples and to mixed cellularity samples. Red arrows on right indicate clusters of caspases and interleukines genes with tightly coregulated expression
Discussion
One of the potential applications of cDNA arrays in cancer research is the development of tumour classi®cations which would re¯ect the clinical and biological diversity of cancer more accurately than current histopathological classi®cations. So far, in HD, the technology has only been applied to cell lines (Kapp et al., 1999) , but not to tissue samples. In this study, we pro®led 34 lymphoid samples including 21 cases of HD tissues.
Previous gene expression analyses of single H/RS cells have provided clues about the pathogenesis of HD (Cossman, 2001; Cossman et al., 1999; Messineo et al., 1998) . Despite the relative scarcity of H/RS and the predominance of the reactive cellular background in HD lesions, our data were obtained using total HD tissue samples and cell lines representing some of the cell types included in HD tissues. Such a strategy, which consists to simultaneously analyse the gene expression pro®les of both complex tissue samples and cell lines has proved to be useful by others (`virtual dissection'; Alizadeh et al., 2001) , in particular in NHL Shaer et al., 2001) . Our data further suggest that the global tumour microenvironment in¯uences the course of the disease and must be taken into consideration when trying to de®ne molecular classi®cation of tumours. This is specially relevant in HD lesions, where the biological interactions between malignant and bystander cells are particularly intense.
The dierences in transcriptional patterns we observed among HD samples provided a molecular basis for the histoclinical heterogeneity of the disease. A hierarchical clustering program, based on the gene expression pro®les, identi®ed three dierent molecular subsets of disease with distinct response to therapy and clinical outcome. Groups A and C contained patients with CR (all) and favourable clinical outcome (all except one) who bene®ted from treatment, whereas group B included all patients whose disease progressed during standard therapy and died. These correlations were observed whatever the source of analysed sample, i.e. primary tumour or relapse. This was illustrated by two samples (10326 and 10088), corresponding to relapses sensitive to treatment, which segregated with good outcome primary tumours. These results suggest that the gene expression pro®ling of HD is able to separate accurately HD cases in GOHD and BOHD groups and to provide a prognosis-oriented classi®ca-tion of HD. Furthermore, gene expression pro®ling should add to the prediction of HD outcome since some patients, who had been attributed an unfavourable prognostic using classical factors, were molecularly classi®ed close to GOHD cases and indeed had a good outcome. Conversely, one patient with fatal outcome, who had been attributed a favourable prognostic using classical factors, was molecularly classi®ed with BOHD cases. Anticipating the response to subsequent therapy would have important therapeutic implications by preventing some patients from being overtreated and by identifying those in whom standard treatment is likely to fail. However, despite their statistical signi®cance, it must be stressed that the correlations were not perfect, probably re¯ecting some degree of residual heterogeneity within our molecular groups. For example, the sample 8487 clustered in a branch of good outcome (group A), but corresponded to a patient who relapsed and died 2 years later. Similarly, samples 8177 and 9393 were classi®ed in the bad outcome molecular group (group B), although the corresponding patients responded to treatment and were alive at 5 and 3 years from biopsy. Thus, pro®ling a larger cohort of patients is obviously required to determine whether cDNA arrays could capture the whole diversity of HD and be used in the future to improve management of patients.
The classi®cation of HD samples was principally based on the combined expression pro®les of three prominent gene clusters. As shown in Figure 2 , most of these genes exhibited large variations of expression levels between the subsets of samples. The identity of the discriminant genes is relevant not only as new potential prognostic or predictive markers, but also as potential therapeutic targets. Most genes overexpressed in the BOHD subset were highly expressed in the HFF ®broblastic cell line (blue cluster), thereby suggesting à ®broblastic signature' in BOHD samples. Indeed, these genes were related to ®broblast activation or function (PDGFRB, Collagen), but also to angiogenesis (Endostatin) or extracellular matrix remodelling (MFAP2, MMP2, MMP3, TIMP1). This may re¯ect an early molecular transition toward extensive ®brosis and lymphoid depletion. The overexpression of MK167 and TNFa in BOHD was in accordance with previous observations (Morente et al., 1997; Warzocha et al., 1998) . The second gene cluster (brown cluster), overexpressed in nodular sclerosis GOHD, contained many cytokine genes, re¯ecting the presence of high amounts of cytokines released within the tumour tissue. It also included genes involved in signal transduction in response to virtually all types of stimuli transmitted by cytokines and antigen receptors, such as STAT3, previously shown to be activated in H/RS cells (Chen et al., 2001) , and MAP2K6 (Stein et al., 1996) . Altogether, these data suggest an intense tracking of intercellular signals between neoplastic and reactive cells within GOHD tissues, which may have a favourable in¯uence on the outcome by contributing to regulate tumour growth. This gene cluster also included many genes involved in cell death induction, such as APAF, BAX, BID, Caspase 8, TP53, and TRAIL (Li and Yuan, 1999) . Some of these apoptotic genes are expressed in H/RS cells Xerri et al., 1994 Xerri et al., , 2000 and are probably involved in dysregulation of the NF-kB pathway (Hinz et al., 2001; Izban et al., 2001) . Their upregulation in GOHD was consistent with the view of a global increase of apoptosis in tumour tissues of GOHD when compared with BOHD. Resistance to chemotherapy has been linked to inhibition of apoptosis (Friesen et al., 1996) and Caspase 8 seems to be specially involved as an executioner caspase in drug-induced apoptosis (Engels et al., 2000) . This might explain why upregulation of apoptotic inducers was associated with good sensitivity to therapy and favourable outcome in our study. The correlation concerning Caspase 8 and BID was interesting since Caspase 8 is expressed in HRS cells (Xerri et al., 2000) and induces apoptosis by BID cleavage (Li and Yuan, 1999) , which thus could be a preferential apoptotic pathway in HD. This subset of apoptotic genes also included the key cell death inducer TP53, corroborating previous immunohistochemical studies indicating that HD cases with high number of P53-expressing cells have a better prognosis (Xerri et al., 1994) . The third gene cluster (orange cluster), underexpressed in nodular sclerosis BOHD, included two tumour suppressor genes PTEN and DCC. PTEN codes for a phosphatase bearing a negative regulatory role in the growth of lymphoid cells (Ge and Rudiko, 2000; Hyun et al., 2000) . Its expression is decreased in acute leukaemia and NHL (Dahia et al., 1999) . The PTEN de®ciency observed in BOHD cases might cause inadequate responsiveness to autocrine and paracrine pathways operating in HD, thus favouring aggressive behaviour of these tumours. This de®ciency might act in synergy with the overexpression of ERBB2 (blue gene cluster) in BOHD cases to induce the constitutive activation of the transcription factor NF-kB; indeed, ERBB2 overexpression activates NF-kB via the AKT kinase signalling pathway which can be inhibited by the tumour suppressor PTEN (Pianetti et al., 2001; Zhou et al., 2000) . Such an activation is a key step in HD pathogenesis (Staudt, 2000) and aects the sensitivity of cancer cells to treatment-induced apoptosis (Oya et al., 2001; Shaer et al., 2001) . Finally, the underexpression of the PMS2 mismatch repair gene might also contribute to resistance to chemo-and radiotherapy (Prolla, 1998) . However, it remains to determine whether expression of these genes is localized in malignant cells.
In conclusion, this study highlights the great potential of cDNA array technology in HD for tumour classi®cation. These encouraging results call for further analysis of larger series of patients with more genes to determine whether gene expression pro®ling could improve the management of HD.
Materials and methods
Characteristics of HD patients
Twenty-one fresh tumour biopsy specimens of classical HD were obtained from 20 dierent patients. Samples were collected at the time of the initial diagnosis (13 cases), the ®rst relapse (six cases), or the initial diagnosis and the ®rst relapse (one case). A portion of each sample was submitted to conventional histopathological processing and standard immunophenotyping. The adjacent piece was quickly frozen in liquid nitrogen. Clinicopathological characteristics of the patients are summarized in Table 1 . The prognosis of patients (favourable or unfavourable) was de®ned by using classical prognostic factors. For localized disease stages (Ann-Arbor stages I and II), these factors were age, sex, sedimentation rate, bulky disease, and B-symptoms; the prognosis of patients with at least one pejorative factor was considered as unfavourable. For patients with disseminated disease, we used the International Prognostic Score (Hasenclever and Diehl, 1998) : poor prognosis was attributed to patients with at least two pejorative factors. All patients received standard chemotherapy according to their prognostic category and to usual recommendations (Canellos et al., 1992) . Radiotherapy consisted of involved ®elds in patients with bulky disease. Response to treatment was estimated by usual criteria: complete response (CR) was de®ned as the disappearance of all known sites of disease and progressive disease (PD) was de®ned by the appearance of any new lesion or increase in the size of any measurable lesion by at least 50%. The survival of patients was measured from the time of analysed biopsy until the last follow-up visit or cancer-related death. Five patients who did not respond to therapy and died from disease were considered as the bad outcome HD (BOHD) cases (samples 2511, 8651, 9036, 9823, 18022) . Fifteen patients who achieved CR and were alive without disease at the last follow-up visit were considered as the good outcome HD (GOHD) group (samples 3883, 3998, 4434, 4914, 5117, 5157, 5234, 6267, 8177, 8683, 8685, 9201, 9393, 10088, 10326).
HD cell lines and non-HD samples
To help the interpretation of expression pro®les, we analysed cell lines and samples that represented some of the cell types involved in HD lesions: non-activated peripheral blood Tcells (T rest.) from three healthy donors (pool), peripheral blood T-cells activated (T act.) for 7 days (pool from ®ve healthy donors), T-cells and B-cells sorted from a benign lymph node (LNT and LNB), the HFF (human foreskin ®broblast) ®broblastic cell line and the H/RS-derived cell lines L428, KMH2 and HDLM2 (Drexler, 1993) kindly provided by Dr F Jundt (MDC, Berlin, Germany). We also included lymph node biopsy samples from two benign lymphadenitis (LN1 and LN2), two diuse large B-cell lymphomas (B-NHL-1 and B-NHL2) and one peripheral Tcell lymphoma (T-NHL).
RNA extraction
Total RNA was extracted from samples by lyses in guanidium isothiocyanate and centrifugation over a caesium chloride cusion using standard protocols (Theillet et al., 1993) . RNA integrity was controlled by denaturing formaldehyde agarose gel electrophoresis and by RT ± PCR ampli®cation of the b2-microglobulin gene.
cDNA arrays preparation
Gene expression was analysed using Nylon cDNA arrays made in our facility. They contained spotted PCR products from 1045 selected IMAGE human cDNA clones and control clones (negative controls such as the pT7T3D vector and three poly(A) sequences). Selection was done on the basis of the following criteria: 3' location of the corresponding mRNA sequence, same cloning vector (pT7T3D), host bacteria and insert size. Most genes were selected for a proven or putative implication in cancer and/or in immune reactions (the list is available on the web site: http:/ tagc.univ.mrs.fr/pub/Cancer/). The identity of the most relevant cDNA clones was veri®ed by 5' tag-sequencing of cDNA insert and comparison with sequences in the EST (dbEST) and nucleotide (GenBank) databases at the NCBI. The PCR ampli®cation and the robotical spotting of PCR products onto Hybond-N+membranes (Amersham) were done according to described protocols .
Complex probes and hybridizations
Complex probes were prepared from 5 mg of total RNA by simultaneous reverse transcription and [a-
33 P] dCTP labelling as described (http:/tagc.univ-mrs.fr/pub/Cancer/). Each sample was hybridized on an individual cDNA array. After washes, hybridization images were obtained by scanning in a Fuji-Bas 1500 system. Signals intensities were quanti®ed by a modi®ed version of the BioImage software (Millipore, USA). Quanti®ed data was then normalized as described , making the gene expression levels comparable between all samples. As previously shown , the reproducibility of experiments allowed to consider a twofold change as a threshold value for dierential expression.
Statistical analysis
Hierarchical clustering was applied to the tissue samples and the genes using the Gene Cluster program developed by Eisen et al. (1998) . The expression level of each gene was ®rst logtransformed and then median-centred (relatively to its median expression across all samples), so that the relative variation was shown, rather than the absolute intensity. Clustering was an average linkage clustering using Pearson correlation coecient as similarity metric. The algorithm arranged the order of genes and the order of samples to place those with the most correlated expression close to each other. Results were displayed using the TreeView program (Eisen et al., 1998) . We also used the k-means algorithm included in the Gene Cluster program to compare classi®cations of genes and samples provided by two dierent methods. Survival was estimated using the Kaplan ± Meier method. The treatment response and survival were compared between groups using respectively the w 2 test or the Fisher's test and the log-rank test. A P-value 50.05 was considered signi®cant.
